Cleopatra Hospital Company

As of June 30, 2026, Cleopatra Hospital Company carries a market capitalization of 24.28B, placing it among publicly traded companies globally. Its enterprise value stands at 28.29B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Cleopatra Hospital Company's next confirmed earnings release is scheduled for November 16, 2026.

As of June 30, 2026, Cleopatra Hospital Company has 1.45B shares outstanding.

As of June 30, 2026, Cleopatra Hospital Company trades at a trailing price-to-earnings ratio of 37.65. The price-to-sales ratio is 2.97, and the price-to-book ratio stands at 6.42.

As of June 30, 2026, Cleopatra Hospital Company trades at an EV/EBITDA multiple of 16.45 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.47 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 21.26 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 28.29B versus a market cap of 24.28B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Cleopatra Hospital Company maintains a current ratio of 0.66, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 93.29, indicating elevated leverage, while an interest coverage ratio of 6.34 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Cleopatra Hospital Company posted a return on equity (ROE) of 18.26, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 12.64 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.31, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 9.10, useful for judging operating efficiency across full business cycles. The company generates approximately 1.76M in revenue per employee across its workforce of 4,628.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 13.44 indicates how many times Cleopatra Hospital Company sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Cleopatra Hospital Company recorded 315.97M in income tax expense. That works out to an effective tax rate of 28.61, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.10B, leaving 643.62M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Cleopatra Hospital Company's stock has gained approximately 5.47% over the past 52 weeks. The 50-day moving average sits at 16.09, while the 200-day moving average is 14.67.

Over the twelve months ended June 30, 2026, Cleopatra Hospital Company generated 8.15B in revenue and converted that into 643.62M in net income, yielding earnings per share of 0.54. EBITDA reached 1.72B, while operating income came in at 1.42B.

As of June 30, 2026, Cleopatra Hospital Company holds 448.62M in cash and equivalents against 3.98B in total debt, resulting in a net debt position of 3.36B. Total book value stands at 3.78B, with working capital of -1.41B providing operational flexibility.

Cleopatra Hospital Company produced 1.74B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.20B in capital expenditures, free cash flow totaled -458.29M - equivalent to -0.32 per share.

Over the twelve months ended June 30, 2026, Cleopatra Hospital Company posted a gross margin of 36.98, reflecting its pricing power and cost economics. The operating margin of 17.36 and net profit margin of 7.89 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Cleopatra Hospital Company paid dividends of -NaN per share. The dividend payout ratio of 0.00 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -1.89: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.52, meaning Cleopatra Hospital Company raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Cleopatra Hospital Company's most recent stock split took place on November 2, 2017 with a 279:1960 split ratio.

As of June 30, 2026, Cleopatra Hospital Company has an Altman Z-Score of 3.50, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.